A

fter pricey new hepatitis C treatments emerged a few years ago, public and private payers restricted coverage in order to ease the financial strain on budgets. But even as more competition among drug makers has prompted discounting, payers continue to deny coverage, including to patients who suffer from the most advanced forms of the disease, according to a new analysis.

As of last September, 37 percent of patients with little to moderate trace of the disease were denied coverage, a mostly steady increase from 27 percent in October 2015. Meanwhile, 24 percent of those severe forms of hepatitis C were denied, up from 15 percent during the same time period. These figures represent an overall trend that includes commercial and government payers.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • here to bring in to notice I’ve treated the cases of hepatitis c effectively in cases where the liver damaged to cirrhosis even after the proper courses of hep c antibiotics , with homeopathic medicines i’m able to witness liver rejuvenating more then 90 %

    • Please do not dumb this place down with fake snake oil medicine when there are great curative meds out there with essentially no side effects.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.